Published
Video length: 2 min.
Article written by
The ANSM, the drug agency, announces that it is preparing to take legal action concerning the publication of a controversial study, signed by Didier Raoult. The former director of the Marseille IHU published a study in March on the supposed effectiveness of treatments such as hydroxychloroquine, a study of more than 30,000 patients with Covid.
The noose seems to be tightening around Didier Raoult. In a column published last week in Le Monde, sixteen learned societies had denounced its methods during the health crisis. ANSM, the drug agency, confirmed on Saturday June 3 that it was going to file a complaint. For the signatories, who regretted the lack of reaction from the institutions, this is good news. “It’s a strong act”reacted Dominique Deplanque, president of the French Society of Pharmacology and Therapeutics. “It is an act expected by the medical community which tries to work, in terms of drug research, in an appropriate way, while respecting the law.”
A legal framework not respected
The pre-publication of a study, not yet scientifically reviewed, co-signed by Didier Raoult in early April, is in question. This reaffirms the effectiveness of hydroxychloroquine as a treatment against Covid. His detractors denounce a wild therapeutic trial on more than 30,000 patients between March 2020 and December 2021. According to the ANSM, the legal framework for conducting such an investigation would not have been respected, which the microbiologist refutes.
View comments